Each year around this time I check up on my past year’s predictions for the stem cell field. For 2015 I made 20 predictions. You can see past 10 predictions lists for 2013 and 2014. It’s pretty interesting to look back at where the focus was in past years and what my crystal ball yielded […]
How did my 20 stem cell predictions for 2015 fare? Read More »
What countries are doing disproportionately well given their size on their stem cell research? When reading through the ISSCR 2015 program you can understand why everyone wants to go to the US for their postdoc as it seems like most of the work being presented is US-based. In fact, this is more than true with
What countries are ‘punching above their weight’ in stem cell space? Read More »
Masayo Takahashi (高橋 政代) on IPSC Trial for Macular Degeneration By Michael Cea Stem Cell Analyst & Advocate (editor’s note: piece was originally posted on Michael’s blog here; follow Michael on Twitter @msemporda) Masayo Takahashi interview Having followed closely the developments in programs using pluripotent based therapeutics I was fortunate during ISSCR2015 to have the opportunity to
Masayo Takahashi (高橋 政代) on IPSC Trial for Vision Read More »
Each year towards the end of December I make predictions for the coming year as I did for 2015. In the past I usually make a top 10 prediction list, but for this year I made 20 predictions. Admittedly some of them may have been more hopes than predictions. At mid-year today on June 30th,
How are my 20 stem cell predictions for 2015 doing? Read More »
The path to the clinic is a slow and arduous activity, frustrating not only to the researcher and patient, but investors and biotech companies. Successful clinical translation of technologies requires a balance of science, streamlined translation and funding. To develop fantastic science and then realise the most important components cannot be adapted to the clinical
Biotech Talks #ISSCR2015: StemCells Inc, Semma, ViaCyte, & Le Blanc Read More »
A new stem cell clinical trial for Multiple Sclerosis (MS) in Canada is raising hopes amongst patients and researchers. According to the Ottawa Citizen, the trial will be led by Dr. Mark S. Freedman (pictured, photo from Ottawa Hospital), director of the multiple sclerosis research unit at The Ottawa Hospital and “The Canadian trials which
Landmark New Stem Cell Trial for Multiple Sclerosis Raises Hopes Read More »
2015 Review of Vogelstein “Bad Luck” Cancer & Stem Cell Paper in Science January 02, 2015 2014 What Does New Paper Mean for Future of Nuclear Transfer ES Cells? November 9, 2014 Encouraging New Paper on ACT Stem Cell-Based Trial for Macular Degeneration October 14, 2014 Top 10 Takeaways From Harvard Stem Cell Diabetes
Post-Publication Paper Reviews & Commentaries Read More »
Every year I do a list of top predictions for the coming year for the stem cell and regenerative medicine field. For example, you can see past top 10 predictions lists for 2013 and 2014. What’s in store for 2015 from the stem cell crystal ball? There is so much going on that for this
Stem Cell Predictions for 2015 Read More »
It’s been a seemingly rather quiet year on the FDA regulatory front in the US when it comes to direct-to-consumer stem cell interventions even as the number of dubious stem cell clinics continues to skyrocket. I requested an interview with the FDA to cover the key pressing issues in this arena. I want to thank
FDA on Key Stem Cell Regulatory Issues & Its Own Research Read More »
StemCells Inc. is a top biotech company developing stem cell-based therapies. They have a deep pipeline that includes already ongoing trials for a variety of diseases. I invited company leadership to do an interview and they graciously accepted. Below is the interview with CFO Greg Schiffman (picture at left from LinkedIn) including what I thought
Interview with StemCells Inc. leadership on hot topics Read More »